Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
Single Patient Expanded Access Treatment Plan For The Investigational Product Narsoplimab
The purpose of the EAP is to provide access to hematopoietic stem cell transplant-associated
 thrombotic microangiopathy (HSCT-TMA) patients who may benefit from treatment with
 narsoplimab based on the medical judgement of their respective physicians.
-  Patient (adult or pediatric) must have undergone allogeneic or autologous
 hematopoietic stem cell transplant (HSCT)

 -  Patient must be capable of understanding an informed consent form (ICF) or the parent
 or legal guardian of the patient is able to understand and sign a written ICF prior to
 the initiation of any treatment procedures.

 -  Patient must have HSCT- TMA defined as having thrombocytopenia and evidence of
 microangiopathic hemolytic anemia.